In its quarterly report, Takeda noted the post-operative gastrointestinal dysfunction drug it was developing with Theravance didn’t meet its endpoints.
Novavax’s double whammy: Stellar vaccine results and mass layoffs
The deferral of R&D relates to the suspension of all preclinical research, including drug discovery projects focused on identifying inhibitors of DNA damage repair.
Otonomy lays off all employees, begins liquidation process